Safety and efficacy of etelcalcetide, an intravenous calcimimetic, for up to 52 weeks in hemodialysis patients with secondary hyperparathyroidism: results of a post-marketing surveillance in Japan
ConclusionThis was the first real-world, large-scale, long-term observational PMS of etelcalcetide in Japan. We did not observe any new safety concerns. Etelcalcetide was associated with clinically relevant improvements in serum iPTH and maintenance of serum cCa, P, and ALP levels.
Source: Clinical and Experimental Nephrology - Category: Urology & Nephrology Source Type: research
More News: Calcium | Dialysis | Drugs & Pharmacology | Gastroenterology | Hemodialysis | Hormones | Hyperparathyroidism | Japan Health | Laboratory Medicine | Nutrition | Parenteral Nutrition | Urology & Nephrology